To determine whether an MRI-based Alzheimer disease (AD) signature biomarker can detect tau-related neurodegeneration in preclinical AD, and to assess whether AD signature cortical thinning is associated with cognitive changes in cognitively normal (CN) older individuals.
Isolated amyloidosis is the earliest stage of preclinical Alzheimer disease (AD), followed by neurodegeneration and then subtle cognitive decline. 1 However, recent work has observed that some cognitively normal (CN) individuals have neurodegeneration (e.g., AD-like brain atrophy on structural MRI) independent of amyloidosis. [2] [3] [4] These observations motivate the investigation of tau-related neurodegenerative process in preclinical AD. In addition, discrepant data exist regarding the relationships between amyloidosis or neurodegeneration and cognitive decline in preclinical AD. 3, 5 Neurodegeneration can be measured using the hippocampal volume or cortical thickness within the topography affected by AD (i.e., "AD signature"). 6, 7 The AD signature has been shown to predict prognosis in individuals without dementia, 8 although an important gap remains. Specifically, the AD topography has been derived primarily as a function of clinical assessment and not biomarkers. Many supposed CN older persons may have biomarker evidence of AD pathology. 9 Some individuals with clinically defined AD do not have biomarker evidence of AD pathology. 10 Here, we refined the AD signature using a cohort of clinical and biomarker-confirmed CN and symptomatic AD individuals. In a separate group of CN individuals (n 5 188), we investigated whether abnormal CSF biomarker of tau pathology was associated with neurodegenerative changes (AD signature cortical thinning or hippocampal atrophy) in preclinical AD. We also examined whether amyloidosis (reduced CSF b-amyloid [Ab] 42) mediated the effects of tau on neurodegeneration. We assessed the impact of neurodegeneration or amyloidosis on cognition in CN individuals.
METHODS Participants. Participants were research volunteers enrolled in longitudinal studies of memory and aging at the Knight Alzheimer's Disease Research Center at Washington University in Saint Louis. Recruitment procedures have been previously published. 11 Inclusion criteria were as follows: (1) age 65 years or older, (2) brain MRI and CSF collection completed within 12 months of clinical assessment, and (3) normal cognition or mild dementia due to AD, indicated by a Clinical Dementia Rating (CDR) of 0 and 1, respectively, 12 assessed at the time closest to MRI scanning and CSF collection. Participants (n 5 308) were divided into 2 cohorts. Cohort 1 was used for definition of the topography of AD signature while cohort 2 was used for analyzing the relationships among MRI-based biomarkers (cortical thickness within AD signature and hippocampal volume), CSF biomarkers (Ab42 and tau), and cognitive measures.
Standard protocol approvals, registrations, and patient consents. The Human Research Protection Office at Washington
University in Saint Louis School of Medicine approved this study. Written informed consent was obtained from each participant. The guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology 13 were followed if applicable.
Clinical and neuropsychological assessments. The participant and a collateral source underwent separate semistructured interviews conducted by experienced clinicians. The presence or absence of dementia was determined by clinicians according to the principle of intraindividual decline relative to prior functional level. 14 A diagnosis of dementia due to AD was made according to standard criteria. 14 All participants completed a neuropsychological battery that assessed the following domains: episodic memory, executive function, visuospatial ability, and semantic. For each domain, a composite score was formed by averaging z scores of individual tests (appendix e-1 on the Neurology ® Web site at Neurology.org). This assessment was performed within 2 months of clinical evaluation.
CSF collection and APOE genotyping. After an overnight fast, CSF (20-30 mL) was obtained and analyzed for Ab42, tau, and phosphorylated tau 181 by plate-based ELISA (INNOTEST; Innogenetics, Ghent, Belgium). 15 Genotyping for APOE was conducted using procedures previously reported. 16 Structural MRI acquisition and preprocessing. Participants were scanned on either Siemens 3T Trio (n 5 110 in cohort 1 or n 5 155 in cohort 2) or 1.5T Vision (n 5 10 in cohort 1 or n 5 33 in cohort 2) scanner (Siemens Medical Systems, Erlangen, Germany). High-resolution structural scans were obtained with a T1-weighted magnetization-prepared rapid gradient echo sequence. Images were processed with FreeSurfer (version 5.10) (http://surfer.nmr.mgh.harvard.edu) (appendix e-2).
Definition of the topography of AD signature. The topography of AD signature was identified in cohort 1 comprising participants with mild AD (CDR 1, n 5 20) and a portion of CN participants (CDR 0, n 5 100). The CN participants were randomly chosen from CN individuals who were negative for CSF Ab42 (.500 pg/mL) and CSF tau (,500 pg/mL). 17 All participants with mild AD had either reduced CSF Ab42 (#500 pg/mL) or elevated Pittsburgh compound B binding (mean cortical binding potential $0.18). 17 Demographics and biomarker data for cohort 1 are provided in table 1.
For each participant in cohort 1, following the preprocessing of structural MRI data, the cortical surface representing the gray-white boundary was inflated into a sphere. 18 The inflated spheres were registered to a common spherical coordinate system that aligned cortical folding patterns across participants. 19 The surface maps of cortical thickness were compared between the mild AD and CN participants using a general linear model with adjustment for age, sex, the presence of APOE e4 allele, and scanner type (3T Trio vs 1.5T Vision). The group difference map was thresholded at a vertex-wise p , 0.001 and cluster size $100 mm 2 . The participants with mild AD exhibited cortical thinning in the entorhinal cortex, fusiform gyrus, inferior, middle and superior temporal gyri, superior and inferior parietal lobules, posterior cingulate gyrus, and precuneus (figure 1). These regions hereafter are collectively referred to as the AD signature.
Measurements of AD signature cortical thickness and hippocampal volume in CN individuals. Demographics and biomarker data for cohort 2 (n 5 188) are provided in table 2. For each participant included in cohort 2, AD signature regions, as identified above, were mapped back to this participant's individual space. Thickness values were obtained from each region Table 1 Demographic characteristics of the cohorts used for definition of AD signature regions
CN AD
No. 100 20
Mean age (SD), y 71 ( and averaged across all AD signature regions to form a composite score. In addition, hippocampal volumes were measured using FreeSurfer's subcortical stream. 20 The details of FreeSurfer's subcortical stream have been previously documented. 20 Briefly, the hippocampus was segmented using automated procedures that examined variations in voxel intensities and spatial relationships to classify subcortical regions. 20 Hippocampal volume was calculated for each participant as the product of the voxel volume and the number of voxels. Hippocampal volumes were then averaged across hemispheres and adjusted for intracranial volume. For each of the samples scanned with 3T Trio (n 5 155) or 1.5T Vision (n 5 33) scanner, individual composite scores of AD signature cortical thickness and adjusted hippocampal volumes were transformed to z scores using corresponding mean and SD derived from this sample.
Statistical analysis. The present statistical approach was informed by existing studies, which have found that (1) the relationship between CSF Ab42 and brain atrophy differs in Ab42-positive vs Ab42-negative individuals (i.e., an interaction between the continuous and categorical measures of CSF Ab42), 21, 22 (2) the interaction between CSF Ab42 and CSF phosphorylated tau 181 is related to brain atrophy, 23 and (3) Ab mediates the effect of tau on neurodegeneration (autopsy data). 24 Thus, we analyzed the associations of AD-associated atrophy with CSF biomarkers using equation 1, which includes the interactions between the continuous and categorical measures of CSF Ab42, between the continuous and categorical measures of CSF tau, between CSF Ab42 (categorical) and CSF tau (categorical), and between CSF Ab42 (categorical) and CSF tau (continuous): Here, AD-associated atrophy denotes the z scores of AD signature cortical thickness or hippocampal volume. CSF_Ab42 and CSF_tau denote the continuous measures of CSF Ab42 and CSF tau, respectively. Ab_status and tau_status were categoricaldefined as positive if CSF Ab42 #500 pg/mL and CSF tau $500 pg/mL, respectively, and negative if CSF Ab42 .500 pg/mL and CSF tau ,500 pg/mL, respectively. 17 Age, sex, and APOE genotype (the presence vs absence of e4 allele) were used as covariates. The interactions were first tested and reported if confirmed. After any detected interaction involving Ab_status or tau_status, relationships between AD-associated atrophy and CSF biomarker were assessed separately within individuals who were positive or negative for the involved biomarker using equation 2: Multiple regression models were used to assess whether cognitive measures were associated with AD signature cortical thickness, hippocampal volume, CSF Ab42, and CSF tau in CN individuals. Specifically, composite scores of each cognitive measure (i.e., episodic memory, executive function, visuospatial, and semantic) were used as dependent variables separately. For each model, AD signature cortical thickness, hippocampal volume, CSF Ab42, and CSF tau were analyzed individually to determine which of them explained a significant portion of the variance (i.e., R 2 ). Furthermore, the 4 independent variables were examined recursively to determine which one explained a significant additional portion of the variance (i.e., increase in R 2 or ΔR 2 ) after accounting for the other 3. All models included age, sex, education, and APOE genotype (the presence vs absence of e4 allele) as covariates. Analyses were implemented using SPSS (version 21.0; IBM Corp., Armonk, NY) with a statistical threshold for significance of p , 0.05, corrected for multiple comparisons for equation 1.
RESULTS

Associations of AD signature cortical thickness
with CSF Ab42 and CSF tau in CN individuals. Analyses of cohort 2 using equation 1 found interactions between CSF Ab42 (continuous) and Ab status (categorical) (p 5 0.02), and between CSF tau (continuous) and tau status (categorical) (p 5 0.01), but not between Ab status and tau status (p 5 0.84), and not between CSF tau and Ab status (p 5 0.53) regarding AD signature cortical thickness (figure e-1A). Since observed interactions suggested that the relationship between AD signature and CSF Ab42 (continuous) was different regarding Ab status and that the relationship between AD signature and CSF tau (continuous) was distinct regarding tau status, AD signature-CSF biomarker relationships were analyzed separately within biomarker-negative or -positive group using equation 2. Within the CSF Ab42-positive (#500 pg/mL, n 5 104) and CSF Ab42-negative (.500 pg/mL, n 5 84) groups, the relationship between CSF Ab42 and AD signature cortical thickness was not found (both p $ 0.13) after adjusting for age, sex, APOE e4, and CSF tau. An inverse relationship was observed between CSF tau and AD signature cortical thickness in the CSF tau-positive group ($500 pg/mL, n 5 46) (partial h 2 5 0.15, p 5 0.01), but no relationship was seen in the CSF tau-negative group (,500 pg/mL, n 5 142) (p 5 0.84) after adjusting for age, sex, APOE e4, and CSF Ab42 (table e-1).
Associations of hippocampal volume with CSF Ab42 and CSF tau in CN individuals. Analyses of cohort 2 using equation 1 revealed an interaction between CSF Ab42 and Ab status (p 5 0.01), but not between Ab status and tau status and not between Ab status and CSF tau (both p $ 0.71) regarding the hippocampal volume. Neither main effects of CSF tau or tau status nor the interaction between them was observed (all p $ 0.30) for the hippocampal volume (figure e-1B). Since hippocampal volume was differentially associated with CSF Ab42 (continuous) according to Ab status, as indicated by the presence of CSF Ab42-Ab status interaction, we analyzed the hippocampal-CSF Ab42 association separately within the CSF Ab42-negative or -positive group using equation 2. A positive relationship was seen between CSF Ab42 and hippocampal volume in the CSF Ab42-positive group (#500 pg/mL) (partial h 2 5 0.07, p 5 0.009), but not in the CSF Ab42-negative group (.500 pg/mL) (p 5 0.79) after adjusting for age, sex, APOE e4, and CSF tau (table e-2). Results are presented in appendix e-3 regarding evaluation of the choice of CSF biomarker cutoffs for studied relationships.
Associations of cognitive performance with AD signature cortical thickness, hippocampal volume, CSF Ab42, and CSF tau in CN individuals. AD signature cortical thickness, hippocampal volume, CSF Ab42, and CSF tau were first analyzed individually regarding each cognitive composite (episodic memory, executive function, visuospatial, and semantic) after controlling for age, sex, education, and APOE e4. Hippocampal volume or CSF Ab42 explained a portion of the variance in episodic memory (R 2 5 0.02, p 5 0.03, and R 2 5 0.03, p 5 0.02, respectively). After accounting for each other, AD signature cortical thickness, and CSF tau, CSF Ab42 explained an additional portion of the variance in episodic memory (ΔR 2 5 0.02, p 5 0.03) while hippocampal volume was not noteworthy (ΔR 2 5 0.02, p 5 0.07). Episodic memory had no relationship with AD signature cortical thickness or CSF tau (both p $ 0.58). AD signature cortical thickness explained some of the variance in visuospatial performance (R 2 5 0.02, p 5 0.03) and continued to account for the same amount of variance after controlling for hippocampal volume, CSF Ab42, and CSF tau. Visuospatial performance had no association with hippocampal volume, CSF Ab42, or CSF tau (all p $ 0.25). Neither executive nor semantic composite scores had any notable relationship with AD signature cortical thickness, hippocampal volume, CSF Ab42, or CSF tau (all p $ 0.10).
DISCUSSION Our work demonstrates that increased CSF tau was related to AD signature cortical thinning but not reduced hippocampal volume in CN individuals with higher CSF tau levels. In contrast, decreased CSF Ab42 was associated with reduced hippocampal volume but not AD signature cortical thinning in CN individuals with lower CSF Ab42 levels. In particular, the effect of increased CSF tau or decreased CSF Ab42 was not attributed to age, sex, and APOE genotype. In addition, AD signature cortical thinning was associated with lower visuospatial performance. Reduced CSF Ab42 was related to poorer performance on episodic memory.
AD-like brain atrophy parallels amyloidosis in preclinical AD. [2] [3] [4] However, the pathophysiologic correlates of Ab-independent atrophy remain unclear. Our work shows that AD-like neurodegeneration (i.e., AD signature cortical thinning) has a direct relationship with abnormal biomarker of tau pathology. Moreover, the topography of AD signature largely parallels the initiation (entorhinal) and early progression (posterior cingulate and temporal neocortex) of neurofibrillary tangles. 25 This topographic correspondence suggests that the observed CSF tau-cortical atrophy association may reflect tangle-related neurodegeneration in the brain. This finding also indicates that the refined AD signature can detect early neurodegeneration in preclinical AD.
Studies of autopsy 24 and transgenic mice 26 postulate that Ab mediates the effect of tau on neurodegeneration, with tau-related neurodegeneration more prevalent in individuals with higher Ab burden than in those with lower Ab burden. We assessed this theory within the entire cohort but found no significant difference in the association of CSF tau and AD signature cortical thickness with respect to Ab status (i.e., CSF Ab42-positive vs CSF Ab42-negative). A secondary analysis within the CSF tau-positive group showed that a significant association of CSF tau with AD signature cortical thickness was seen in CSF Ab42-positive but not CSF Ab42-negative individuals (data not shown). However, the difference in the CSF tau-AD signature association remained nonsignificant regarding Ab status within the CSF taupositive group. The present observation may provide some preliminary evidence in support of the view that cortical neurodegeneration results from the synergistic effect of Ab and tau. 23, 24, 27 Further work assessing this view with more sensitive and specific measure of tau pathology (e.g., tau imaging tracer) is needed.
Longitudinal studies have observed an accelerating decline in visuospatial ability in CN individuals who subsequently developed AD dementia compared with those who remained cognitively unimpaired. 28 The present result suggests a pathophysiologic correlate for the previous observation by showing that visuospatial decline is explained by subtle cortical neurodegeneration that at least is partly linked to tau pathology. In addition, we observed that lower performance on episodic memory is related to Ab deposition or hippocampal atrophy, the former consistent with several recent reports 29, 30 but not others. 3 Notably, after accounting for each other, the effect of Ab on memory remained significant while the relationship with hippocampal atrophy was marginal. This result suggests that the impact of Ab on memory may be independent of its effects on neurodegeneration in CN individuals. The mechanisms underlying observed Ab-related lower memory performance remain to be explored.
Overall, our data suggest that Ab and tau are preferentially associated with spatially distinct neurodegeneration during the preclinical phase of AD. Specifically, Ab deposition alone may be sufficient for the atrophy in the hippocampus but not AD signature regions, which instead is related to tau pathology, or likely the mediation of Ab on tau. These results not only agree with the emerging view of existence of "Ab-dependent" and "Ab-independent" pathways to preclinical AD, [2] [3] [4] [31] [32] [33] but also stress that the spatial distribution of the different pathways needs to be considered. In addition, our work demonstrates that memory and nonmemory domains may be differentially affected by Ab and neurodegeneration. This result explains several recent observations 27, 34 that the joint presence of amyloidosis and neurodegeneration may be required for the emergence of clinical symptoms of AD.
Our work has limitations. We observed the association between higher CSF tau and AD signature cortical thinning after adjusting for age (and other confounders). However, age adjustment may be unable to completely remove the aging effect that is associated with tau pathology and cortical atrophy. Longitudinal studies are needed to estimate the extent to which observed CSF tau-related AD signature atrophy is specific to AD. 
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